DETERMINATION OF THE CAMPTOTHECIN DERIVATIVES CPT-11 AND SN-38 IN URINE AND SALIVA BY MICELLAR ELECTROKINECTIC CHROMATOGRAPHY

被引:3
|
作者
Marques, F. F. C. [1 ,2 ]
Cunha, A. L. M. C. [1 ]
Sa, A. [1 ]
Aucelio, R. Q. [1 ]
机构
[1] Pontificia Univ Catolica Rio de Janeiro, Dept Quim, BR-22451900 Rio De Janeiro, RJ, Brazil
[2] Univ Fed Fluminense, Dept Quim Analit, Rio De Janeiro, Brazil
关键词
Irinotecan; Micellar electrokinetic capillary chromatography; Normal stacking mode; SN-38; TISSUE-CULTURE MEDIA; LIQUID-CHROMATOGRAPHY; IRINOTECAN; CAPILLARY; PHARMACOKINETICS; METABOLISM; PLASMA; AGENTS;
D O I
10.1080/00032719.2012.677985
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The anti-cancer synthetic drug irinotecan (CPT-11) and its active metabolite SN-38 have been determined by micellar electrokinetic capillary chromatography (MEKC). The detection of the analytes was made at 368 nm and their separation took less than 7 min using a borate buffer (pH 8.8 at 25 mmol L-1) solution containing sodium dodecyl sulfate (45 mmol L-1) and acetonitrile (13.5% v/v). On-line analyte concentration (normal stacking mode) and the use of a highly sensitive cell (Z shaped cell) improved detection limits (at the 10(-8) mol L-1 level). Recovery in fortified human saliva was 108 +/- 5%, in agreement with the result achieved with the reference HPLC method. For the analysis of urine from rats submitted to a single dose of CPT-11 and SN-38, camptothecin was used as internal standard enabling recoveries close to 100% when compared to the results achieved using HPLC.
引用
收藏
页码:1849 / 1861
页数:13
相关论文
共 50 条
  • [1] INTRACELLULAR ROLES OF SN-38, A METABOLITE OF THE CAMPTOTHECIN DERIVATIVE CPT-11, IN THE ANTITUMOR EFFECT OF CPT-11
    KAWATO, Y
    AONUMA, M
    HIROTA, Y
    KUGA, H
    SATO, K
    CANCER RESEARCH, 1991, 51 (16) : 4187 - 4191
  • [2] Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
    Jeff A. Sloan
    Pamela Atherton
    Joel Reid
    Henry C. Pitot
    Charles Erlichman
    Larry Schaaf
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 241 - 249
  • [3] Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide
    Sloan, JA
    Atherton, P
    Reid, J
    Pilot, HC
    Erlichman, C
    Schaaf, L
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (03) : 241 - 249
  • [4] Liposomalization of SN-38 as active metabolite of CPT-11
    Sadzuka, Y
    Takabe, H
    Sonobe, T
    JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) : 453 - 459
  • [5] KINETIC-STUDIES OF THE HYDROLYSIS AND LACTONIZATION OF CAMPTOTHECIN AND ITS DERIVATIVES, CPT-11 AND SN-38, IN AQUEOUS-SOLUTION
    AKIMOTO, K
    KAWAI, A
    OHYA, K
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1994, 42 (10) : 2135 - 2138
  • [6] Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography
    Chollet, DF
    Goumaz, L
    Renard, A
    Montay, G
    Vernillet, L
    Arnera, V
    Mazzo, DJ
    JOURNAL OF CHROMATOGRAPHY B, 1998, 718 (01): : 163 - 175
  • [7] SELECTIVE AND SENSITIVE DETERMINATION OF LACTONE AND HYDROXY ACID FORMS OF CAMPTOTHECIN AND 2 DERIVATIVES (CPT-11 AND SN-38) BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
    AKIMOTO, K
    GOTO, A
    OHYA, K
    JOURNAL OF CHROMATOGRAPHY, 1991, 588 (1-2): : 165 - 170
  • [8] Preclinical evaluation of CPT-11 and its active metabolite SN-38
    Lavelle, F
    Bissery, MC
    Andre, S
    Roquet, F
    Riou, JF
    SEMINARS IN ONCOLOGY, 1996, 23 (01) : 11 - 20
  • [9] Population pharmacokinetics of CPT-11 and its metabolites SN-38 and SN-38 glucuronide in relation to diarrhea.
    Xie, R
    Mathijssen, RH
    Sparreboom, A
    Verweij, J
    Karlsson, MO
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P28 - P28
  • [10] PHARMACOLOGICAL CORRELATION BETWEEN TOTAL DRUG CONCENTRATION AND LACTONES OF CPT-11 AND SN-38 IN PATIENTS TREATED WITH CPT-11
    SASAKI, Y
    YOSHIDA, Y
    SUDOH, K
    HAKUSUI, H
    FUJII, H
    OHTSU, T
    WAKITA, H
    IGARASHI, T
    ITOH, K
    JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (01): : 111 - 116